JP5345637B2 - κ選択的オピオイド受容体アンタゴニスト - Google Patents

κ選択的オピオイド受容体アンタゴニスト Download PDF

Info

Publication number
JP5345637B2
JP5345637B2 JP2010543182A JP2010543182A JP5345637B2 JP 5345637 B2 JP5345637 B2 JP 5345637B2 JP 2010543182 A JP2010543182 A JP 2010543182A JP 2010543182 A JP2010543182 A JP 2010543182A JP 5345637 B2 JP5345637 B2 JP 5345637B2
Authority
JP
Japan
Prior art keywords
disorder
ethanol
pharmaceutically acceptable
acceptable salt
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010543182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524850A (ja
JP2011524850A5 (OSRAM
Inventor
ヌリア・ディアス・ブエソ
デイビッド・リー・マッキンジー
チャールズ・ハワード・ミッチ
コンセプシオン・ペドレガル−テルセロ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2011524850A publication Critical patent/JP2011524850A/ja
Publication of JP2011524850A5 publication Critical patent/JP2011524850A5/ja
Application granted granted Critical
Publication of JP5345637B2 publication Critical patent/JP5345637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010543182A 2008-01-22 2009-01-13 κ選択的オピオイド受容体アンタゴニスト Active JP5345637B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (3)

Publication Number Publication Date
JP2011524850A JP2011524850A (ja) 2011-09-08
JP2011524850A5 JP2011524850A5 (OSRAM) 2012-02-23
JP5345637B2 true JP5345637B2 (ja) 2013-11-20

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543182A Active JP5345637B2 (ja) 2008-01-22 2009-01-13 κ選択的オピオイド受容体アンタゴニスト

Country Status (32)

Country Link
US (2) US7709522B2 (OSRAM)
EP (1) EP2252581B1 (OSRAM)
JP (1) JP5345637B2 (OSRAM)
KR (1) KR101172170B1 (OSRAM)
CN (1) CN101925576B (OSRAM)
AR (1) AR070158A1 (OSRAM)
AU (1) AU2009206653B2 (OSRAM)
BR (1) BRPI0907382B8 (OSRAM)
CA (1) CA2713025C (OSRAM)
CO (1) CO6290644A2 (OSRAM)
CY (1) CY1113071T1 (OSRAM)
DK (1) DK2252581T3 (OSRAM)
DO (1) DOP2010000222A (OSRAM)
EA (1) EA017484B1 (OSRAM)
EC (1) ECSP10010365A (OSRAM)
ES (1) ES2388708T3 (OSRAM)
HR (1) HRP20120558T1 (OSRAM)
IL (1) IL206038A (OSRAM)
JO (1) JO2797B1 (OSRAM)
MA (1) MA32751B1 (OSRAM)
MX (1) MX2010007849A (OSRAM)
MY (1) MY163014A (OSRAM)
NZ (1) NZ586225A (OSRAM)
PE (1) PE20091317A1 (OSRAM)
PL (1) PL2252581T3 (OSRAM)
PT (1) PT2252581E (OSRAM)
SI (1) SI2252581T1 (OSRAM)
TN (1) TN2010000306A1 (OSRAM)
TW (1) TWI422369B (OSRAM)
UA (1) UA100715C2 (OSRAM)
WO (1) WO2009094260A1 (OSRAM)
ZA (1) ZA201003908B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168958B2 (en) 2018-02-08 2021-11-09 DEON Optical Design Corporation Sighting scope

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907230A2 (pt) * 2008-01-22 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto
CN101925576B (zh) * 2008-01-22 2013-02-06 伊莱利利公司 κ-选择性阿片受体拮抗剂
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
CA2858752C (en) 2011-12-09 2019-12-31 Research Triangle Institute 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP4574210A3 (en) 2017-03-17 2025-10-15 The Scripps Research Institute Kappa opioid receptor antagonists and products and methods related thereto
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL308221A (en) 2021-05-04 2024-01-01 Janssen Pharmaceuticals Inc Preparations and methods for treating depression
IL314179A (en) * 2022-01-10 2024-09-01 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
US20250064779A1 (en) * 2022-01-10 2025-02-27 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156210A (zh) * 2022-03-07 2024-12-17 杨森制药公司 纯形式的结晶阿替卡普兰
EP4489730A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
JP2025508051A (ja) 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ，インコーポレーテッド 大うつ病性障害の治療に使用するためのアチカプラントの多形形態
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
JP3706307B2 (ja) * 1999-05-12 2005-10-12 エフ．ホフマン−ラ ロシュ アーゲー イミダゾジアゼピン誘導体
WO2002029418A1 (en) * 2000-10-05 2002-04-11 Hanns Mohler Selective anxiolytic therapeutic agents
US6528518B2 (en) * 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
US7119196B2 (en) * 2002-03-28 2006-10-10 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
ES2392200T3 (es) * 2002-09-19 2012-12-05 Eli Lilly & Company Ésteres de diarilo como antagonistas del receptor opiáceo
DE602004016127D1 (de) * 2003-03-07 2008-10-09 Lilly Co Eli Antagonisten der opioidrezeptoren
AU2004220112A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
JP2007516284A (ja) * 2003-12-22 2007-06-21 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
CA2559207A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
DE602005022572D1 (de) * 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
ES2318472T3 (es) * 2004-03-15 2009-05-01 Eli Lilly And Company Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad.
EP1735268B1 (en) * 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CN101522614B (zh) 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
CN101925576B (zh) * 2008-01-22 2013-02-06 伊莱利利公司 κ-选择性阿片受体拮抗剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168958B2 (en) 2018-02-08 2021-11-09 DEON Optical Design Corporation Sighting scope

Also Published As

Publication number Publication date
HK1146822A1 (en) 2011-07-15
CA2713025C (en) 2012-12-04
IL206038A0 (en) 2010-11-30
JP2011524850A (ja) 2011-09-08
BRPI0907382A2 (pt) 2015-07-21
MX2010007849A (es) 2010-08-09
KR20100095639A (ko) 2010-08-31
PL2252581T3 (pl) 2012-10-31
TN2010000306A1 (en) 2011-11-11
CO6290644A2 (es) 2011-06-20
JO2797B1 (en) 2014-03-15
WO2009094260A1 (en) 2009-07-30
US7709522B2 (en) 2010-05-04
KR101172170B1 (ko) 2012-08-07
CN101925576A (zh) 2010-12-22
DOP2010000222A (es) 2015-11-15
EA201070877A1 (ru) 2010-12-30
AU2009206653B2 (en) 2013-07-18
ES2388708T3 (es) 2012-10-17
US8173695B2 (en) 2012-05-08
EP2252581B1 (en) 2012-06-20
MA32751B1 (fr) 2011-11-01
TW200936129A (en) 2009-09-01
ECSP10010365A (es) 2010-08-31
UA100715C2 (ru) 2013-01-25
CY1113071T1 (el) 2016-04-13
US20100197669A1 (en) 2010-08-05
SI2252581T1 (sl) 2012-09-28
AR070158A1 (es) 2010-03-17
CN101925576B (zh) 2013-02-06
NZ586225A (en) 2012-05-25
EP2252581A1 (en) 2010-11-24
BRPI0907382B1 (pt) 2020-03-10
AU2009206653A1 (en) 2009-07-30
ZA201003908B (en) 2011-11-30
PT2252581E (pt) 2012-08-31
BRPI0907382B8 (pt) 2021-05-25
TWI422369B (zh) 2014-01-11
DK2252581T3 (da) 2012-07-16
PE20091317A1 (es) 2009-09-03
CA2713025A1 (en) 2009-07-30
HRP20120558T1 (hr) 2012-10-31
MY163014A (en) 2017-07-31
IL206038A (en) 2013-11-28
EA017484B1 (ru) 2012-12-28
US20090186873A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
JP5345637B2 (ja) κ選択的オピオイド受容体アンタゴニスト
WO2010124089A2 (en) Methods for treating dependence
US20110015208A1 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
ZA200306193B (en) Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders.
CA2946153C (en) Use of known compounds as d-amino acid oxidase inhibitors
WO2010148121A2 (en) Benzothiazole derivatives
JP2011512414A (ja) 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体
JP2011512414A5 (OSRAM)
MXPA06000077A (es) Composiciones que contienen un inhibidor selectivo de la recaptacion de serotonina y un antagonista del receptor 5-ht2a.
HK1146822B (en) Kappa selective opioid receptor antagonist
RS108904A (sr) N,n-disupstituisani diazocikloalkani korisni za tretman poremećaja cns usled serotonergijske disfunkcije
HK40042967B (zh) 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
HK40042967A (en) Use of known compounds as d-amino acid oxidase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130814

R150 Certificate of patent or registration of utility model

Ref document number: 5345637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250